Latent TB Detection Market is expected to reach US$ 1,684.86 million in 2027

by Sameer Joshi or 10-Feb-2021
Request For Sample

Report : Latent TB Detection Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Test (Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA)); End User (Hospitals, Diagnostic Centers, Laboratories, and Others) and Geography

Advancements in Tuberculosis Diagnosis to be a Prevalent Trend in Latent TB Detection Market
According to our new market research study on “Latent TB Detection Market to 2027 – COVID-19 Impact and Global Analysis – by Test and End User,” the market is expected to reach US$ 1,684.86 million in 2027 from US$ 1,131.82 million in 2019. The market is estimated to grow with a CAGR of 5.2% from 2020-2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. The growth of the market is attributed to the increasing prevalence of tuberculosis and government initiatives to promote tuberculosis detection. However, multidrug resistant tuberculosis (MDR-TB) is likely to hamper the growth of the market to a certain extent.
Based on end user, the latent TB detection market is segmented into hospitals, diagnostic centers, laboratory and others. The hospitals segment held the largest share of the market in 2019. Moreover, the same segment is estimated to register the highest CAGR in the market during the forecast period.
Fluorescent stamping, antigen detection, ELISA, modified culture methods, and antigen preparations are among the advanced procedures practiced for the diagnosis of TB across the world. Manufacturers and researchers are consistently working toward finding new and viable solutions that are based on potent technologies to accurately diagnose TB. For instance, in July 2020, Cepheid, Inc. and The Foundation for Innovative New Diagnostics (FIND) introduced a new drug-resistant tuberculosis-profiling test that provides test results in 90 min. Moreover, the accessibility of blood-based diagnostics in the form of interferon γ release assays (IGRAs) have helped clinicians deliver reliable test results for diagnosing latent TB infection with high specificity and sensitivity. Thus, the consistent advancements in TB diagnosis is likely to be a prevalent trend in the market during the coming years.
The COVID-19 pandemic was first reported in December 2019 in Wuhan (China). The COVID-19 pandemic has threatened the national TB programs worldwide. The WHO have also notified that pandemic is threatening to reverse global progress against tuberculosis. The COVID-19 response has affected multiple sectors of public health, recommended preventive screening, and clinical care around the globe.
QIAGEN, BioMeriux S.A., F. Hoffmann La-Roche Ltd., BD, ARKRAY, Inc., Abbott, Serum Institute of India Pvt. Ltd, Oxford Immunotec Ltd, Lionex GmbH are among the leading companies in the latent TB detection market.
The report segments global latent TB detection market as follows:
By Test
  • Tuberculin Skin Test (TST)
  • Interferon Gamma Released Assay (IGRA)
By End User
  • Hospitals
  • Diagnostic Centers
  • Laboratories
  • Others
By Geography
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Spain
    • Italy
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • South Africa
  • South and Central America (SCAM)
    • Brazil
    • Argentina

Contact Us

Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: